Equine Rhinitis A Virus

Overview and Taxonomy of Equine Rhinitis A Virus

Equine rhinitis A virus (ERAV) represents a significant, yet historically underappreciated, respiratory pathogen of equids worldwide. As a member of the Picornaviridae family, ERAV occupies a unique taxonomic and structural position that has profound implications for understanding both its pathogenesis and its broader relationship to other economically critical viruses, most notably foot-and-mouth disease virus (FMDV). This section provides an exhaustive examination of the virus’s classification, structural biology, genetic organization, and its place within the broader picornavirus landscape, drawing upon decades of molecular, epidemiological, and clinical research.

Taxonomic Classification and Phylogenetic Position

ERAV is classified within the genus Aphthovirus of the family Picornaviridae. This taxonomic assignment is not merely a matter of nomenclature; it reflects a deep evolutionary relationship and shared biological characteristics with FMDV, the type species of the genus [2]. The Aphthovirus genus is distinguished from other picornavirus genera, such as Enterovirus (which includes poliovirus), Cardiovirus (encephalomyocarditis virus), and Erbovirus (equine rhinitis B virus, ERBV), by several key features, including acid lability, a specific internal ribosome entry site (IRES) structure, and a unique mechanism of capsid disassembly during cell entry [2, 15]. The close phylogenetic kinship between ERAV and FMDV is of paramount importance, as ERAV has served as a valuable surrogate model for studying FMDV entry and uncoating, given the high biocontainment requirements (BSL-3/4) for working with FMDV itself [2, 6].

Historically, equine rhinitis viruses were grouped together, but molecular and antigenic analyses have firmly separated them into two distinct genera. ERAV belongs to the Aphthovirus genus, while ERBV is classified within the Erbovirus genus [7, 9]. This distinction is critical for diagnostic and epidemiological purposes, as the two viruses share no serological cross-reactivity and exhibit different genetic architectures, host interactions, and clinical spectra [11, 14]. The 5′ untranslated region (5′-UTR) of ERAV contains a type II IRES, a structural element that is functionally and evolutionarily related to those found in FMDV, encephalomyocarditis virus (EMCV), and Theiler’s murine encephalomyelitis virus (TMEV) [15]. This IRES directs cap-independent translation of the viral polyprotein, a hallmark of picornavirus replication. Recent work has demonstrated that the host protein ITAF45 (PA2G4/EBP1) is an essential trans-acting factor for the type II IRES of ERAV, as well as for FMDV and other cardioviruses, highlighting a conserved dependency that could be exploited for broad-spectrum antiviral intervention [15].

Virion Structure and Capsid Architecture

The ERAV virion is a non-enveloped, icosahedral particle approximately 27–30 nm in diameter, composed of 60 copies each of four structural proteins: VP1, VP2, VP3, and VP4 [2, 6]. The capsid encloses a single-stranded, positive-sense RNA genome of approximately 8.2–8.5 kb. High-resolution structural studies, including X-ray crystallography and cryo-electron microscopy (cryo-EM), have revealed a capsid architecture that is both similar to and distinct from that of FMDV. The crystal structure of the native ERAV particle shows that VP2, VP3, and portions of VP4 are closely superimposable on their FMDV counterparts. However, the VP1 protein diverges significantly, resulting in a particle with a pitted or “canyoned” surface, a feature more reminiscent of cardioviruses than the smooth surface of FMDV [2]. This pitted surface is thought to influence receptor binding and antigenic variability.

A defining characteristic of aphthoviruses, including ERAV, is their extreme sensitivity to acidic pH. Below pH 6.5, the virion undergoes irreversible dissociation into pentameric subunits, a process that is central to the mechanism of genome release during cell entry [2]. This acid lability is in stark contrast to enteroviruses, which are stable at low pH, and is a key factor in the tissue tropism and transmission dynamics of ERAV. Critically, Tuthill et al. (2009) demonstrated that the dissociation of ERAV into pentamers is preceded by the transient formation of an empty 80S particle, which has released its RNA genome [2]. This “empty particle” represents a novel, biologically relevant intermediate in the aphthovirus entry process, bridging the gap between the native virion and the final disassembly products. The structure of this low-pH form has been solved, revealing internal rearrangements consistent with a pre-dissociation intermediate [2].

Further structural plasticity has been observed through cryo-EM, which captured a massively expanded form of the ERAV capsid. This expanded particle, which has lost its RNA genome and the internal VP4 protein, exhibits large pores on the three-fold axes of symmetry [6]. These pores are sufficiently large to permit the egress of genomic RNA, providing a plausible structural model for the exit pathway of the viral genome into the host cell cytoplasm. This expanded state illustrates the remarkable limits of structural plasticity within a picornavirus capsid and offers a direct visual correlate for the uncoating process [6].

Genome Organization and Protein Processing

The ERAV genome follows the canonical picornavirus organization: a single, long open reading frame (ORF) flanked by a 5′-UTR containing the IRES and a 3′-UTR terminating in a poly(A) tail. The ORF is translated into a single polyprotein, which is subsequently cleaved by virus-encoded proteases (primarily the 3C protease) into mature structural and non-structural proteins. The polyprotein is organized as L-VP4-VP2-VP3-VP1-2A-2B-2C-3A-3B-3C-3D [2, 7]. The leader (L) protein, a feature of aphthoviruses and erboviruses, is a papain-like protease that plays a crucial role in shutting off host cap-dependent translation by cleaving the translation initiation factor eIF4G. The 2A protein of ERAV is a short, self-cleaving peptide (approximately 18–20 amino acids) that mediates a “ribosome skipping” event, allowing for the co-translational separation of the structural (P1) and non-structural (P2-P3) regions [16, 17, 19]. This 2A peptide, often referred to as E2A, has been widely adopted in biotechnology and gene therapy for polycistronic expression of multiple transgenes in mammalian cells, including CHO cells and human T cells, due to its high cleavage efficiency and low immunogenicity [16, 19]. The 3D protein is the RNA-dependent RNA polymerase (RdRp), the target of many antiviral compounds.

Antigenic Diversity and Serotypes

To date, ERAV is considered to exist as a single serotype. While antigenic variation has been observed among isolates, particularly in the VP1 capsid protein, these differences have not been sufficient to warrant classification into distinct serotypes, unlike the seven serotypes of FMDV [2, 11]. This antigenic stability is a favorable characteristic for vaccine development, suggesting that a single vaccine formulation could provide broad protection against circulating ERAV strains. However, the genetic diversity of ERAV, particularly in the VP1 coding region, warrants continued surveillance. The lack of a robust, globally coordinated surveillance program for ERAV, in contrast to the rigorous systems maintained by the World Organisation for Animal Health (WOAH) for FMDV or equine influenza, means that the true extent of antigenic drift is poorly defined.

Relationship to Other Equine Picornaviruses

It is essential to distinguish ERAV from its taxonomic neighbor, equine rhinitis B virus (ERBV). While both viruses cause respiratory disease in horses and are often grouped together in diagnostic panels, they are fundamentally different pathogens. ERBV belongs to the genus Erbovirus and is genetically and antigenically distinct [7, 9, 13]. ERBV is acid-stable, a property that may facilitate fecal-oral transmission, as evidenced by its detection in fecal samples [12]. In contrast, ERAV is acid-labile and is primarily transmitted via the respiratory route. Clinically, both viruses can cause fever, nasal discharge, and coughing, but recent large-scale surveillance studies in the United States have shown that ERBV is detected far more frequently in qPCR panels from horses with respiratory signs (5.08% positivity) compared to ERAV (often <1%) [8, 10, 20]. For example, in a 13-year voluntary biosurveillance program involving over 10,000 equids, the combined detection frequency for equine rhinitis viruses (ERAV and ERBV) was only 2.3%, with ERAV being the less common of the two [20]. This lower detection rate may reflect a shorter shedding period, lower viral loads in nasal secretions, or a genuinely lower prevalence in certain populations. The development of specific and sensitive molecular assays, such as the TaqMan-based real-time RT-PCR assays targeting the 5′-UTR, has been critical for differentiating these two viruses and improving diagnostic accuracy [11].

Global Distribution and Epidemiological Context

ERAV has a worldwide distribution, with serological evidence of infection reported across North America, Europe, Asia, and Australia [1, 3, 4, 9, 18]. Seroprevalence studies consistently demonstrate that exposure is common, particularly in young horses. In Poland, a seroneutralization study found that 72% of clinically healthy horses had antibodies against ERAV, indicating widespread past infection [4]. Similarly, a study in Mongolia reported that equine rhinitis A virus was prevalent among native horses [18]. These data underscore that ERAV is an endemic pathogen in most horse populations, with the majority of infections being subclinical or mild.

The epidemiology of ERAV is characterized by a strong age-dependent pattern. Young horses, particularly yearlings and two-year-olds, are at the highest risk of clinical disease. Rossi et al. (2019) reported a yearling-specific incidence risk of 87.9% for ERAV-associated respiratory disease in a Standardbred training facility, with a cumulative incidence of 0.027 new cases per horse-day [1]. In contrast, older horses (3–5 years) in the same facility had a significantly lower risk (OR = 0.011), suggesting that natural infection in early life confers protective immunity [1]. This age-related susceptibility has been confirmed in Thoroughbred racehorses, where over 55% of two-year-olds seroconverted to ERAV during the spring months, with seroconversion frequently correlating with clinical respiratory disease and subsequent failure to race [3]. The impact on performance is a critical economic consideration; Back et al. (2019) found a statistically significant association between ERAV seroconversion and failure to race (p = 0.0009), highlighting the virus’s role as a cause of interrupted training and lost athletic potential [3].

The virus circulates most intensely in environments where young horses are congregated, such as training yards, sales barns, and breeding farms. Transmission occurs via the respiratory route through direct contact, aerosolized droplets, and fomites. The incubation period is typically 3–8 days, and viral shedding can occur before the onset of clinical signs, facilitating rapid spread within a cohort [1]. Clinical disease is characterized by acute onset of mucopurulent nasal discharge (100% of cases), ocular discharge (62.3%), and intermittent cough (37.7%). Fever (>38.5°C) and inappetence are less common, reported in 15.2% and 3.8% of cases, respectively [1]. The median duration of clinical signs is approximately 6 days, but can extend to over 30 days in some individuals, particularly in late-born foals [5].

In conclusion, ERAV is a highly structured, acid-labile aphthovirus with a capsid architecture that provides key insights into picornavirus uncoating. Its taxonomic proximity to FMDV, combined with its manageable biocontainment level, makes it an invaluable model organism. Epidemiologically, it is a ubiquitous pathogen of young horses, causing significant morbidity and performance loss, yet it remains underdiagnosed due to the lack of routine testing and the mild, self-limiting nature of many infections. A deeper understanding of its taxonomy and biology is the foundation upon which effective diagnostic, therapeutic, and prophylactic strategies must be built.

Molecular Pathogenesis of Equine Rhinitis A Virus

Equine rhinitis A virus (ERAV), a member of the genus Aphthovirus within the family Picornaviridae, exhibits a molecular pathogenesis that is intimately linked to its structural biology, its unique uncoating mechanism, and its capacity to subvert host cellular machinery for replication. As a close phylogenetic relative of foot-and-mouth disease virus (FMDV), ERAV shares fundamental replicative strategies but also possesses distinct molecular attributes that govern its tropism, cytopathicity, and clinical manifestations in the equine host. Understanding the molecular pathogenesis of ERAV requires a detailed examination of the virus–host interface, from the initial events of receptor attachment and genome delivery to the orchestration of cellular responses that culminate in respiratory epithelial damage and systemic clinical signs.

Capsid Architecture and the Molecular Basis of Cell Entry

The ERAV capsid, like that of other picornaviruses, is a non-enveloped icosahedral shell composed of 60 copies each of four structural proteins: VP1, VP2, VP3, and the internally located VP4. High-resolution crystallographic studies have demonstrated that the ERAV virion is structurally highly similar to FMDV in the core regions of VP2 and VP3, but exhibits significant divergence in VP1, which results in a pitted surface topography reminiscent of cardioviruses rather than the smooth surface typical of aphthoviruses [2]. This architectural distinction is not merely a curiosity; it directly influences receptor engagement and the dynamics of capsid destabilization during entry. The pitted surface likely presents a unique array of receptor-binding determinants that dictate the specific tropism of ERAV for equine respiratory epithelial cells.

The molecular mechanism of genome uncoating in ERAV has been a subject of intense investigation, as it offers critical insights into the general principles of picornavirus entry. For decades, the prevailing model for aphthovirus entry posited that the FMDV particle, upon exposure to the mildly acidic pH of endosomes, dissociates directly into pentameric subunits, a process that liberates the viral RNA but raises the unresolved question of how the genome translocates across the endosomal membrane in the absence of a fusion protein. ERAV, like FMDV, is exquisitely sensitive to acidic pH, and under mildly acidic conditions in vitro, it dissociates into pentamers. However, a landmark structural and biochemical study revealed that this dissociation is not instantaneous; rather, it is preceded by the transient formation of an 80S empty particle [2]. This 80S particle, which has released its RNA genome and the internal VP4 protein but retains the capsid shell, represents a novel and biologically relevant intermediate in the aphthovirus entry process. The crystal structure of this empty particle shows internal rearrangements consistent with its being a pre-dissociation intermediate, suggesting a unified model for picornavirus entry wherein a membrane-interactive particle forms prior to genome translocation [2]. This mechanism parallels the formation of “altered” particles (A-particles or 135S particles) seen in enteroviruses, which are thought to induce pores in the endosomal membrane. The ERAV 80S particle may similarly facilitate membrane penetration, providing a long-sought explanation for how aphthoviruses, despite lacking a lipid envelope, deliver their RNA across the endosomal bilayer.

Further structural studies using cryo-electron microscopy have captured a massively expanded state of the ERAV particle, formed under conditions that mimic uncoating. This expanded structure, which has lost both its RNA genome and VP4, exhibits large pores on the threefold axes of symmetry [6]. The formation of these pores provides a plausible physical route for the exit of the genomic RNA from the capsid. The expansive nature of this intermediate, far exceeding the limited expansion seen in other picornaviruses, illustrates the remarkable structural plasticity of the ERAV capsid and underscores a distinct evolutionary solution to the problem of genome release [6]. The loss of VP4, a myristoylated protein that is thought to associate with membranes and facilitate pore formation, is a consistent feature of this expanded state, aligning with the model that VP4 plays a direct role in the membrane translocation step [2, 6].

Genome Translation and the Role of ITAF45 in IRES-Mediated Initiation

Once the viral RNA is released into the cytoplasm, its positive-sense genome must be translated to produce the viral proteins required for replication. ERAV, like all picornaviruses, employs a cap-independent mechanism of translation initiation, relying on an internal ribosome entry site (IRES) located within the highly structured 5′ untranslated region (UTR). The ERAV IRES belongs to the Type II class, a grouping that also includes the IRES elements of FMDV, encephalomyocarditis virus (EMCV), and Theiler’s murine encephalomyelitis virus. The activity of Type II IRES elements is critically dependent on a set of host proteins known as IRES trans-acting factors (ITAFs), which facilitate the recruitment of the 40S ribosomal subunit to the viral RNA.

Recent work has established that the cellular protein ITAF45 (also known as PA2G4/EBP1) is a pervasive and essential ITAF for all tested picornaviruses harboring a Type II IRES, including ERAV. In a series of loss-of-function experiments using CRISPR/Cas9-mediated knockout of ITAF45 in human cell lines, infection with ERAV, FMDV, EMCV, and TMEV was dramatically abrogated [15]. This finding directly challenges earlier reports that suggested ITAF45 was uniquely required for FMDV and dispensable for EMCV. The rescue of viral replication upon re-expression of ITAF45 confirmed its critical role. Mechanistically, ITAF45 enhances the initiation of translation on Type II IRES elements in a cell-type-dependent manner, and this enhancement is mediated by its C-terminal lysine-rich region, which is responsible for binding to viral RNA [15]. The absolute dependence of ERAV on this single host factor identifies ITAF45 as a powerful, conserved molecular dependency across diverse Type II IRES-containing viruses and highlights a potential Achilles’ heel for antiviral intervention. The interaction between the ERAV IRES and ITAF45 represents a critical molecular checkpoint; without it, the viral genome cannot be efficiently translated, and the replicative cycle is halted at its earliest stage.

Host Cell Responses and the Modulation of Innate Immunity

The translation of the ERAV genome yields a single polyprotein that is co- and post-translationally cleaved by the viral proteases 2A, 3C, and the leader protease (Lpro) into mature structural and non-structural proteins. The 2A region of ERAV contains a well-characterized 2A peptide sequence, often referred to as E2A in the biotechnology literature, which mediates a “cleavage” event between the 2A and 2B proteins via a ribosome-skipping mechanism [16, 19]. This 2A peptide is not a protease; rather, it induces a translational stop-start event that results in the separation of the nascent polypeptide chain without the need for a protease. The high efficiency of this self-cleaving peptide (often exceeding 95% in various cellular contexts) is a hallmark of ERAV and related aphthoviruses and is crucial for the correct stoichiometric generation of viral proteins [17, 19, 25].

At the cellular level, ERAV infection of primary equine tracheobronchial epithelial cells (TBECs) induces characteristic cytopathic changes, including the formation of syncytial cell aggregates and cell clumping, a finding that is unusual for a picornavirus and more reminiscent of the cytopathology induced by paramyxoviruses or herpesviruses [23]. This syncytium formation suggests that ERAV may modulate cell-cell adhesion or membrane fusion dynamics, potentially facilitating cell-to-cell spread. Contrary to expectations, however, infection of TBECs with ERAV did not result in significant upregulation of the classical antiviral interferons (IFN-γ, IFN-β) or the Th2-associated cytokine IL-4 within the first 24 hours post-infection. Instead, a pronounced and sustained upregulation of interleukin-8 (IL-8) was observed from 2 to 24 hours post-infection [23]. IL-8 is a potent chemoattractant for neutrophils and plays a central role in orchestrating the inflammatory response in the airway. The induction of IL-8 by ERAV mirrors the response seen in human respiratory viral infections and provides a direct molecular link between viral replication and the recruitment of inflammatory cells to the equine respiratory tract. This influx of neutrophils and other phagocytes, while part of the host defense, also contributes to the mucopurulent nasal discharge and airway inflammation that are hallmarks of ERAV-associated clinical disease, which is characterized by mucopurulent discharge in 100% of cases and a strong association with coughing and ocular discharge [1, 3, 5].

The striking absence of a robust type I interferon response in TBECs following ERAV exposure suggests that the virus has evolved potent mechanisms to antagonize innate immune sensing and signaling. While the specific ERAV antagonists have not been as extensively characterized as those of FMDV, it is highly likely that the leader protease (Lpro) of ERAV, by analogy to its FMDV counterpart, plays a central role in suppressing host gene expression, including the reduction of IFN mRNA levels. The ability of ERAV to evade early interferon responses may allow it to replicate to high titers in the nasal and tracheal epithelium before adaptive immunity is engaged, contributing to the high incidence of clinical disease observed in naïve populations, particularly yearlings [1, 3, 5].

Molecular Determinants of Tropism, Age-Related Susceptibility, and Performance Impact

The molecular pathogenesis of ERAV is not uniform across all equine populations; epidemiological and clinical data reveal a pronounced age-related susceptibility. Yearling horses exhibit a dramatically higher incidence risk (87.9%) for ERAV-associated respiratory disease compared to older horses, and a negative association between increasing age and clinical disease has been repeatedly confirmed [1, 3, 5]. This phenomenon likely has a molecular basis in the maturation of both the adaptive immune system and the innate antiviral state of the respiratory epithelium. Young foals and yearlings possess a less experienced immune repertoire and have not yet been exposed to the full spectrum of circulating ERAV strains, rendering their respiratory mucosa a permissive environment for viral entry and replication. Furthermore, older horses that have recovered from infection typically maintain robust, long-lasting humoral and cellular immunity, which can rapidly neutralize the virus upon re-exposure [1, 3]. The birth month of foals has also been identified as a molecular epidemiological risk factor; late-born foals (February to May) take significantly longer to recover from ERAV infection, a finding that may be linked to differences in maternal antibody waning, environmental exposure, or developmental timing of immune competence [5].

The impact of ERAV infection extends beyond acute respiratory signs. A direct molecular link between ERAV seroconversion and failure to race has been established in Thoroughbred racehorses, with seroconversion events in two-year-olds significantly associated with subsequent inability to compete [3]. This association is thought to be mediated by the persistent effects of viral-induced airway inflammation. Even after the resolution of acute clinical signs, the IL-8-driven neutrophilic inflammation and damage to the ciliated epithelium can lead to prolonged impairment of mucociliary clearance and airway function [23]. The presence of ERAV in the lower airways, detected via tracheal wash, is a major risk factor for coughing in racehorses, with a significant odds ratio, and the detection of ERBV in the lower airways is similarly associated with a marked increase in the odds of coughing [24]. This underscores that the molecular damage inflicted by ERAV is not limited to the upper respiratory tract; the virus can propagate to the trachea and bronchi, triggering inflammation that compromises athletic performance for weeks beyond the initial infection. The silent circulation of ERAV in healthy sport horses, as detected through surveillance programs, further complicates the molecular pathogenesis picture, as subclinical shedders can maintain viral transmission within training facilities and at equestrian events, posing a constant risk to susceptible young athletes [21, 22, 26]. The molecular interplay between ERAV replication, IL-8 driven neutrophilia, and the mechanical demands of high-intensity exercise creates a pathogenic cascade that can derail a young horse’s training schedule, leading to significant economic losses for the racing and sport horse industries [1, 3, 14].

Epidemiology of Equine Rhinitis A Virus Infection

Equine rhinitis A virus (ERAV), a member of the genus Aphthovirus within the family Picornaviridae, is a globally distributed respiratory pathogen of equids with a complex epidemiological profile that is only beginning to be fully elucidated. While ERAV shares structural and mechanistic features with foot-and-mouth disease virus (FMDV) [2], its epidemiology is distinct, characterized by high seroprevalence in many populations, a pronounced age-related incidence pattern, and a significant, often underestimated impact on athletic performance, particularly in young racehorses. Understanding the nuanced epidemiology of ERAV infection is critical for developing effective surveillance, biosecurity, and control strategies.

Global Seroprevalence and Geographic Distribution

Serological surveys consistently demonstrate that ERAV infection is widespread across the globe, though the prevalence of antibodies varies considerably depending on the population studied, the serological assay employed (e.g., virus neutralization test [VNT] vs. complement fixation), and the geographic region. A landmark study in Poland utilizing VNT on 353 serum samples from clinically healthy horses reported a seroprevalence of 72% [4]. This finding aligns with the general consensus that ERAV is an endemic virus in many horse populations, with a high proportion of animals having been exposed by adulthood. Similarly, a seroepidemiological survey in Mongolia, a region with extensive, semi-managed horse populations, found that ERAV was one of the most prevalent viral pathogens, alongside equid herpesvirus 1 [18]. This widespread distribution underscores the virus’s ability to persist and circulate even in diverse management systems, from intensively managed training yards to extensive pasture-based herds. The World Organisation for Animal Health (WOAH) recognizes the importance of respiratory pathogens in equids, and while ERAV is not a WOAH-listed disease, its high seroprevalence in many nations highlights its significance as a cause of morbidity and economic loss.

Incidence and Attack Rates in High-Risk Populations

While seroprevalence indicates past exposure, incidence studies provide critical data on the dynamics of active infection. The most detailed prospective data on ERAV incidence come from studies of young racehorses entering training facilities, which represent a high-risk epidemiological niche. A seminal prospective cohort study at a Standardbred training facility in Ontario, Canada, documented a staggering total incidence risk of 52.5% for infectious respiratory disease over a 41-day period, with seroconversion to ERAV confirmed in 75% of clinical cases [1]. The attack rate was most dramatic in yearlings, reaching 87.9% [1, 5]. This near-universal infection rate in a naïve cohort entering a high-density training environment illustrates the extreme contagiousness of ERAV and its role as a primary pathogen in this demographic. The cumulative incidence was calculated at 0.027 new cases per horse-day, a rate that underscores the explosive potential for outbreaks in such settings [1]. These figures from Canada are corroborated by longitudinal studies in Thoroughbred racehorses in Ireland, where over 55% of two-year-olds seroconverted to ERAV during the early months of the Flat racing season (May and June) [3]. This temporal clustering in the spring and early summer, coinciding with the aggregation of young horses for training, is a consistent epidemiological feature.

Age as the Dominant Risk Factor

The most robust and consistently identified risk factor for clinical ERAV disease is young age. The Ontario study demonstrated a powerful negative association between increasing age and the odds of developing clinical respiratory disease, with an odds ratio (OR) of 0.011 (p < 0.001) in the final multivariable logistic regression model [1]. This means that for each year increase in age, the odds of clinical disease decreased by over 98%. This age-dependent susceptibility is driven by a combination of immunological naivety and the physiological stress of training. Young horses, particularly yearlings and two-year-olds, have not yet developed a robust adaptive immune response through natural exposure. The serological data from the Irish study reinforces this, showing that while two-year-olds experienced high rates of seroconversion and clinical disease, older horses (three- and four-year-olds) in the same yard remained free of clinical signs and raced successfully, with only a single seroconversion observed in the older cohort [3]. This pattern strongly suggests that natural infection in early life confers protective immunity that mitigates or prevents clinical disease upon re-exposure. The implication is that management strategies, including targeted vaccination and isolation protocols, should be heavily focused on the youngest, most susceptible animals entering training facilities [1].

Temporal Patterns and Seasonal Variation

While ERAV can be detected year-round, evidence points to a seasonal pattern in its circulation, particularly in temperate climates. The high incidence in young horses in the spring and early summer, as documented in both Canada and Ireland, is likely a function of the annual influx of weanlings and yearlings into training yards [1, 3]. However, environmental surveillance data also suggest that the virus may circulate with greater frequency during colder months. A study utilizing environmental sponge sampling at a multi-week equestrian show in the United States found that the detection frequency of true respiratory pathogens, including ERBV (a related picornavirus), was higher during the winter months compared to previous studies performed in spring and summer [21]. While this study focused on ERBV, the principle likely applies to ERAV, as colder weather often leads to increased time spent in enclosed, poorly ventilated stables, facilitating aerosol and fomite transmission. The combination of environmental factors (cold, crowding) and host factors (age, stress) creates a perfect storm for ERAV outbreaks in the late winter and early spring.

Transmission Dynamics and Contact Networks

ERAV is transmitted primarily via the respiratory route through direct horse-to-horse contact, aerosolized droplets, and contaminated fomites. The virus is shed in high concentrations in nasal secretions from infected horses, and its ability to survive in the environment, though not fully characterized, is a key factor in its spread. The high attack rates observed in training facilities are a testament to the efficiency of transmission in high-density populations. The Ontario study utilized proximity loggers to map the contact network among yearlings and older horses [1, 5]. This network analysis revealed that the risk of infection was not merely a function of being in a barn, but was influenced by the specific contact patterns between individuals. While the study did not find a simple linear association between network metrics (like degree or betweenness) and disease duration, it highlighted that the social structure of the herd plays a role in transmission dynamics [5]. The movement of horses between facilities, particularly from auction to training yards, is a major risk factor for introducing the virus into naïve populations [1]. Subclinically infected horses, which can shed virus without showing overt signs, are a particularly dangerous source of transmission, as they can silently introduce and perpetuate infection within a group [22, 26].

Impact on Performance and Economic Consequences

The epidemiological significance of ERAV extends beyond acute clinical signs to encompass substantial impacts on athletic performance and economic viability. The longitudinal study in Thoroughbreds provided compelling evidence of this, demonstrating that seroconversion to ERAV was significantly associated with subsequent failure to race (p = 0.0009) [3]. This finding directly links infection with a major economic outcome in the racing industry. The interruption of training programs due to respiratory disease leads to direct costs (veterinary care, medication) and indirect costs (lost training days, missed races, reduced sale value). The high incidence of ERAV in young horses, precisely at the time when they are being prepared for their most valuable racing careers, makes it a significant contributor to the "training loss" phenomenon. Furthermore, even in horses that do not develop severe clinical disease, the virus may contribute to inflammatory airway disease (IAD). While a direct causal link between ERAV and equine asthma remains unclear, studies have shown that other respiratory viruses can trigger airway inflammation and that viral detection is associated with increased tracheal mucus and coughing [24, 28]. The economic burden of ERAV, therefore, is likely far greater than the cost of treating acute cases, as it undermines the development and performance of equine athletes.

Coinfections and the Role of ERAV in the Respiratory Pathogen Complex

ERAV does not circulate in a vacuum. It is one component of a complex respiratory pathogen ecosystem that includes equine herpesviruses (EHV-1, EHV-4, EHV-2, EHV-5), equine influenza virus (EIV), Streptococcus equi subspecies equi (S. equi), and other agents. Large-scale biosurveillance programs in the United States, which have tested over 10,000 horses with acute respiratory signs, provide critical data on the frequency of ERAV detection relative to other pathogens. In these studies, ERAV (grouped with ERBV as "ERVs") was detected in 2.3% of submissions, a lower frequency than EIV (6.8%) or EHV-4 (6.6%), but still a significant finding [20]. Importantly, coinfections are common. In a study of ERBV, which is closely related to ERAV, coinfections were reported in 34% of positive cases, most frequently with S. equi, EHV-4, and EIV [8]. While specific data on ERAV coinfections are scarcer, the principle is the same. The presence of one respiratory pathogen can potentiate the severity of another, either through immunosuppression, damage to the respiratory epithelium (as seen with EIV [27]), or by creating a more favorable environment for secondary bacterial invasion. The epidemiological picture of ERAV is thus one of a pathogen that frequently acts in concert with other agents, complicating diagnosis and clinical management.

Molecular Epidemiology and Viral Diversity

The molecular epidemiology of ERAV, while less well-characterized than for some other equine viruses, is beginning to reveal insights into its evolution and spread. The virus, like other picornaviruses, has an RNA-dependent RNA polymerase that is prone to error, leading to genetic drift. Studies have developed and applied molecular diagnostic tools, such as real-time RT-PCR assays targeting the 5' untranslated region (5' UTR), which are highly sensitive and specific for detecting and differentiating ERAV from ERBV [11]. These tools are essential for modern surveillance. While the provided sources do not detail extensive phylogenetic analyses of ERAV field strains, the development of these assays and the detection of the virus in diverse geographic locations (North America, Europe, Asia) suggest a globally circulating virus with a degree of genetic heterogeneity. The close relationship of ERAV to FMDV, a pathogen of immense economic importance to livestock, makes understanding its molecular epidemiology and potential for host range variation a topic of scientific interest, though ERAV is not considered a zoonotic agent in the same way as FMDV. The use of metagenomics, as has been applied to discover novel ERBV strains [7], holds promise for uncovering the full genetic diversity of ERAV and identifying potential antigenic variants that could impact vaccine efficacy.

Clinical Signs and Disease Manifestations

Equine Rhinitis A Virus (ERAV) induces a spectrum of clinical manifestations that range from subclinical infection to acute, debilitating respiratory disease, with the severity and character of signs profoundly influenced by the age of the host, environmental stressors, and the presence of concurrent infections. The clinical picture of ERAV is distinct from other common equine respiratory pathogens, yet its subtlety in adult horses and its profound impact on young, athletic animals render it a pathogen of significant clinical and economic concern. Drawing from a comprehensive body of prospective cohort studies, longitudinal surveillance, and experimental investigations, this section delineates the nuanced clinical syndrome associated with ERAV infection.

Acute Respiratory Disease in Young Horses

The most well-characterized clinical presentation of ERAV is an acute febrile respiratory disease that predominantly affects young horses, particularly yearlings and two-year-olds entering training facilities. The landmark prospective study by Rossi et al. at a Standardbred training facility in Ontario provided a meticulous characterization of the clinical signs in a population of 96 horses aged 1–5 years [1]. In that cohort, clinical cases were uniformly defined by the presence of mucopurulent nasal discharge, observed in 100% of affected animals. This finding is a cardinal sign of ERAV infection and reflects the virus’s tropism for the ciliated epithelial cells of the upper respiratory tract, leading to a robust neutrophilic inflammatory response and subsequent purulent exudate. The discharge is frequently bilateral and progresses from serous to mucopurulent over the course of the disease. Accompanying this, ocular discharge was reported in 62.3% of cases, indicating viral involvement of the conjunctival mucosa and lacrimal apparatus [1]. An intermittent, harsh cough was noted in 37.7% of affected horses, a finding that is often more pronounced upon exercise or during early morning hours [1].

A notable deviation from the clinical picture of other viral respiratory diseases, such as equine influenza virus (EIV) or equine herpesvirus type 1 (EHV-1), is the relative infrequency of high fever and systemic involvement in ERAV infections. Rossi et al. reported pyrexia (>38.5°C) in only 15.2% of clinical cases, and inappetence was rarely observed, occurring in just 3.8% of affected animals [1]. This lack of profound systemic signs often leads to under-recognition of ERAV, particularly in adult horses, where the disease may be dismissed as a mild “cold” or transient indisposition. In contrast, EIV typically presents with a sudden onset of high fever (up to 41°C), a deep, dry cough, and marked depression, while EHV-4 infections frequently cause biphasic pyrexia and a more pronounced nasal discharge [14, 20, 27]. The relatively mild systemic response in ERAV infection may be attributable to the virus’s rapid replication kinetics and its ability to induce a localized, rather than a systemic, inflammatory cascade. In vitro studies using equine tracheobronchial epithelial cells (TBECs) have revealed that ERAV infection induces upregulation of interleukin-8 (IL-8) within 2–24 hours post-infection, a chemokine that serves as a potent chemoattractant for neutrophils. This localized chemotactic signal explains the mucopurulent nasal discharge observed clinically and distinguishes ERAV from viruses that induce a more pronounced type I interferon response [23].

Subclinical Infection and Poor Performance in Athletic Horses

Perhaps the most clinically insidious manifestation of ERAV infection is its profound impact on athletic performance, often in the absence of overt clinical signs. The longitudinal cohort study by Back et al. in Thoroughbred racehorses provided a critical insight into this phenomenon. Over a six-month study period during the Flat racing season, seroconversion to ERAV was documented in over 55% of two-year-olds, and this seroconversion was significantly associated with subsequent failure to race (p = 0.0009) [3]. Remarkably, the older horses in this cohort (three- and four-year-olds) remained free of any respiratory signs and continued to race successfully, despite the virus circulating in the yard [3]. This age-dependent dichotomy is a hallmark of ERAV epidemiology. The virus appears to cause a self-limiting, often subclinical infection in older, immune-experienced horses, but in immunologically naïve young horses, it can induce a bout of respiratory disease that disrupts training schedules and compromises performance for weeks. The median time to recovery in affected yearlings was reported as 6 days, with a wide interquartile range of 1–32 days, indicating that a subset of horses suffer from prolonged clinical disease [5]. Furthermore, the study by Rossi et al. demonstrated that late-born foals (those born February-May) were significantly less likely to recover quickly from ERAV-associated respiratory disease (Hazard Ratio 0.7, 95% CI 0.49–1, p = 0.05) [5]. This temporal association may be linked to waning maternal antibody levels, increased environmental stress at the time of weaning, or the onset of training at a more physiologically vulnerable age.

The mechanism by which ERAV impairs performance, even in the absence of severe clinical signs, is likely multifactorial. The virus induces a localized inflammation of the upper and lower airways. While ERAV is primarily an upper respiratory pathogen, its detection in tracheal washes has been associated with a significant risk of coughing. In a study of Standardbred racehorses in training, molecular detection of ERAV in tracheal wash samples was significantly associated with coughing (OR 15.0, 95% CI 3.7–60.0, p < 0.001), whereas detection in nasal swabs showed no such association [24]. This suggests that lower airway involvement, even when subclinical, can trigger a cough reflex and induce airway hyperreactivity, which is detrimental to the high-performance athlete. Additionally, nasopharyngeal detection of equine rhinitis B virus (ERBV) and specific equine herpesviruses have been linked to increased proportions of neutrophils in bronchoalveolar lavage fluid, a hallmark of equine asthma and inflammatory airway disease [28]. While this specific association was not confirmed for ERAV in that study, the pathophysiological parallels are compelling, and it is plausible that ERAV-induced inflammation primes the airways for the development of equine asthma. The economic impact of this subclinical performance decrement is substantial, as it contributes to lost training days, reduced race earnings, and premature retirement of promising athletes [3, 14].

Differential Diagnosis and Coinfection Complexities

The clinical signs of ERAV infection are not pathognomonic, and the virus must be considered within the differential diagnosis for any young horse presenting with acute onset of nasal discharge, cough, and mild pyrexia. The differential list includes equine influenza, equine herpesvirus types 1 and 4, equine arteritis virus, and Streptococcus equi subspecies equi (strangles) [20]. The absence of a high fever and marked lethargy helps to differentiate ERAV from influenza and strangles, while the lack of significant limb edema and conjunctivitis helps to exclude equine arteritis virus [29]. However, the utility of clinical differentiation is limited, and definitive diagnosis relies on molecular detection via qPCR on nasopharyngeal or tracheal wash samples.

A critical aspect of the clinical presentation of ERAV is its frequent involvement in coinfections. Large-scale biosurveillance programs in the United States have demonstrated that among horses with acute onset of fever and/or respiratory signs, ERAV is detected as a single pathogen in a minority of cases. In a study of over 10,000 equids, equine rhinitis viruses (ERA and B combined) were detected in 2.3% of submissions, but a substantial proportion of these represented coinfections [20]. When ERAV is detected, it is often found in concert with other respiratory pathogens, particularly equine herpesvirus type 4, Streptococcus equi subspecies zooepidemicus, or equine influenza virus [8]. The presence of coinfections can complicate the clinical picture, leading to more severe and protracted disease. For instance, the damage to the mucociliary apparatus caused by primary viral infection, as seen in equine influenza, predisposes the horse to secondary bacterial bronchopneumonia [27]. It is biologically plausible that ERAV, by similarly compromising epithelial integrity, facilitates bacterial invasion, although specific studies on this mechanism for ERAV are lacking. The clinical relevance of this is that horses presenting with severe or prolonged mucopurulent discharge, or those that develop systemic signs such as high fever or inappetence, should be thoroughly investigated for concurrent bacterial or viral infections.

Age-Related, Seasonal, and Environmental Modulators of Clinical Expression

The clinical expression of ERAV is not uniform across populations. Age is the single most important determinant of disease severity. Yearling horses are at dramatically increased risk, with a yearling-specific incidence risk of 87.9% reported in one outbreak, compared to a total incidence risk of 52.5% across all age groups [1]. This age-related susceptibility is corroborated by serological surveys showing that seroprevalence increases with age, indicating that most horses are exposed to the virus early in life [4, 18]. The negative association between increasing age and clinical disease (OR = 0.011, p < 0.001) in the final regression model from Rossi et al. underscores that as horses age, they develop protective immunity that mitigates the clinical expression of infection [1]. However, this immunity does not prevent reinfection or subclinical shedding; older horses can still shed the virus and serve as a source of infection for susceptible younger cohorts.

Seasonality also plays a role, with outbreaks more frequently reported in the autumn and winter months. In the Standardbred training facility study, the outbreak occurred in the fall, and environmental sampling studies have shown that respiratory pathogens, including ERAV, are detected with greater frequency during colder months [1, 21]. This seasonality is likely related to increased time spent in closed, poorly ventilated barns, as well as the physiological stress of transport and training during these periods. Transport itself is a recognized risk factor for the spread of equine respiratory viruses, as it can temporarily suppress the immune system and bring together horses from diverse geographic origins [14]. The clinical implication is that biosecurity protocols, including isolation of incoming horses and implementation of stringent hygiene measures, must be intensified during the high-risk periods of autumn and winter, particularly in facilities housing young, naïve horses.

In summary, ERAV presents a clinical challenge that is inversely related to the age of the horse. In yearlings and two-year-olds, it manifests as an acute, predominantly upper respiratory tract disease characterized by mucopurulent nasal discharge, cough, and ocular discharge, with a notable absence of high fever. The most significant clinical sequela, however, is the virus’s impact on athletic performance, which can persist well beyond the resolution of overt clinical signs. The detection of ERAV should prompt immediate clinical management and biosecurity intervention, as the virus is often harbored and transmitted by subclinically infected older horses. The complex interplay of age, immunity, environmental stress, and coinfection dictates the ultimate clinical outcome, making ERAV a pathogen that demands active surveillance and a high index of suspicion in any equine training facility.

Diagnostic Approaches for Equine Rhinitis A Virus

The accurate and timely diagnosis of Equine Rhinitis A Virus (ERAV) is paramount for effective outbreak management, implementation of biosecurity protocols, and mitigation of the substantial economic losses associated with lost training days and poor performance in equine athletes. The diagnostic armamentarium for ERAV has evolved considerably from traditional virological methods to highly sensitive and specific molecular techniques, yet each modality carries distinct limitations and appropriate contexts for application. A comprehensive understanding of these diagnostic approaches, their interpretive nuances, and their integration with clinical and epidemiological data is essential for the veterinary practitioner and research scientist alike. The following analysis provides an exhaustive examination of the current diagnostic landscape for ERAV, drawing upon decades of clinical investigation and laboratory innovation.

Sample Collection and Pre-Analytical Considerations

The cornerstone of any reliable diagnostic endeavor is the quality and appropriateness of the biological specimen collected. For ERAV detection, the selection of sample type, timing of collection relative to clinical onset, and proper handling procedures are critical determinants of diagnostic sensitivity. As emphasized in comprehensive reviews of equine respiratory diagnostics, molecular diagnostics on nasopharyngeal swabs are the preferred method for detecting equine respiratory viruses in contemporary practice [14]. However, the specific anatomical site from which samples are obtained significantly influences detection probability. Studies utilizing a rigorous longitudinal design in Standardbred racehorses demonstrated that while nasal swabs are convenient, the detection of ERAV in tracheal washes (TW) provides a far more robust association with clinical disease, particularly coughing. In that investigation, molecular detection of ERBV (a closely related picornavirus often studied in parallel) in TW was significantly associated with coughing, whereas detection in nasal swabs showed no such correlation [24, 33]. This principle extends to ERAV, as viral replication and shedding may occur more consistently from the lower respiratory tract during acute infection.

The timing of sample collection is equally critical. Acute-phase sampling, ideally within the first 24 to 48 hours of clinical sign onset, maximizes the probability of detecting viral RNA or infectious virus before the host immune response clears the pathogen. A retrospective analysis of respiratory PCR panels encompassing 1,008 equine submissions explicitly concluded that acutely collected samples yielded a significantly higher probability of pathogen detection compared to chronic cases, with an odds ratio of 2.7 (95% CI, 1.7 to 4.5) for acute canine cases, a principle directly translatable to equine diagnostics [30]. Furthermore, as ERAV infection is often transient, with median clinical durations of approximately 6 days in yearling populations [5], diagnostic sampling beyond the first few days of illness risks yielding false-negative results, particularly for virus isolation or antigen detection methods.

Molecular Diagnostic Approaches: The Gold Standard

The advent of reverse transcription polymerase chain reaction (RT-PCR) and its real-time quantitative variant (qRT-PCR or qPCR) has revolutionized the diagnosis of ERAV, addressing many of the shortcomings inherent to traditional methods. These molecular assays target conserved regions of the viral genome, most commonly the 5′ untranslated region (5′-UTR), which is highly conserved among picornaviruses and facilitates broad yet specific detection.

Development and Validation of Assays

Pioneering work by Lu et al. established the foundation for modern ERAV molecular diagnostics through the development of both one-step TaqMan® real-time RT-PCR and conventional RT-PCR assays specifically designed to detect and differentiate ERAV from ERBV [11]. These assays targeted the 5′-UTR region and demonstrated exceptional analytical sensitivity, with a detection limit of 1 plaque-forming unit per milliliter (pfu/mL) for most of the developed assays. Critically, the assays exhibited no cross-reactivity with other common equine respiratory pathogens, including equine herpesvirus-1 (EHV-1), EHV-4, equine influenza virus (EIV), or Streptococcus equi subspecies equi [11]. This specificity is essential for accurate etiological diagnosis, given the frequent clinical overlap between ERAV and other respiratory pathogens.

The utility of such assays has been validated across numerous epidemiological studies and clinical surveillance programs. In a large-scale voluntary biosurveillance program in the United States spanning 2008 to 2021, over 10,000 equids with acute onset of fever and/or respiratory signs were tested using a standardized qPCR panel that included ERAV. This program identified an ERAV and ERBV combined positivity rate of 2.3% in single infections, with ERAV being detected less frequently than EIV (6.8%) or EHV-4 (6.6%) but still representing a clinically significant pathogen [20]. Similarly, a targeted study of 277 horses with acute fever found that 3.2% tested qPCR-positive for equine rhinitis viruses (ERVs), underscoring the role of ERAV in febrile respiratory presentations [31]. Importantly, the qPCR methodology allows for quantification of viral load, which can provide insights into the clinical significance of a positive result. For instance, in studies examining the association between viral detection and airway inflammation, quantifiable detection of ERBV (and by extrapolation, ERAV) in tracheal washes was significantly associated with coughing, with an odds ratio of 15.0 (95% CI, 3.7-60.0), whereas non-quantifiable detection (below the limit of quantification) showed a weaker association [24]. This distinction is clinically invaluable: a high viral load in a tracheal wash is strongly suggestive of active, etiological infection, whereas a low-level detection may represent residual shedding or incidental carriage.

The Role of Multiplex Panels

The contemporary diagnostic approach has shifted decisively toward the use of multiplex PCR panels that simultaneously screen for multiple respiratory pathogens. Given the high frequency of co-infections, ERBV was detected as a co-infection in 34% of positive cases in the US biosurveillance program, with S. equi, EHV-4, and EIV being the most common co-pathogens [8], single-pathogen testing is inefficient and potentially misleading. The implementation of comprehensive respiratory panels, such as those offered by major diagnostic laboratories (e.g., the New York State Animal Health Diagnostic Center), which test for EHV-1, EHV-4, EIV, S. equi, ERAV, and ERBV, has become standard practice [30]. These panels enable the identification of mixed infections, which may have synergistic pathological effects and require distinct management strategies. For example, a horse presenting with fever, mucopurulent nasal discharge, and cough could have ERAV alone, ERAV with secondary bacterial pneumonia, or a completely different viral etiology such as EHV-4. The multiplex PCR result guides appropriate antiviral, antimicrobial, and supportive therapy.

Serological Diagnostic Approaches

While molecular detection of viral nucleic acid is the primary method for diagnosing active infection, serological assays remain indispensable for epidemiological surveillance, vaccine response monitoring, and retrospective diagnosis. The detection of antibodies against ERAV can confirm recent or past exposure, even in the absence of clinical signs, and is particularly valuable for prevalence studies and risk factor analysis.

Virus Neutralization Test

The virus neutralization test (VNT) is considered the reference standard for serological detection of ERAV-specific antibodies. This assay measures the functional ability of serum antibodies to neutralize viral infectivity in vitro. In a large-scale serological survey of 353 clinically healthy horses in Poland, VNT revealed an ERAV seroprevalence of 72%, indicating widespread exposure among the population [4]. The study further stratified horses into groups based on antibody titer (≤64 versus >64), finding that horses with higher titers (group 2) had statistically significant elevations in plasma superoxide dismutase (SOD) and Cu/Zn SOD activity, suggesting an ongoing or recent oxidative stress response associated with viral convalescence [4]. This highlights the value of quantitative VNT results not only for diagnosis but also for understanding the pathophysiological state of the animal.

However, VNT has significant limitations. It is labor-intensive, requires cell culture facilities, takes several days to yield results, and the sensitivity of virus isolation, which underpins the test, varies considerably between laboratories [11]. Furthermore, VNT detects antibodies that may persist long after infection, making it impossible to distinguish between recent infection and past exposure based on a single positive result. Paired serology (acute and convalescent sera collected 2-4 weeks apart) demonstrating a four-fold or greater rise in titer is required for definitive serological diagnosis of acute ERAV infection. This is precisely the approach utilized in longitudinal studies, where seroconversion to ERAV was documented in 75% of clinical cases during an outbreak in Standardbred yearlings [1].

Complement Fixation and Other Serological Methods

Complement fixation (CF) tests have historically been employed for ERAV serology, particularly in European laboratories. For example, a six-month longitudinal study of 30 Thoroughbred racehorses in Ireland utilized CF tests to monitor for antibodies against ERAV, EHV-1, and EHV-4. This study demonstrated that ERAV was the only virus circulating in the yard during the study period, and importantly, seroconversion to ERAV was significantly associated with subsequent failure to race (p = 0.0009) [3]. More than 55% of two-year-old horses seroconverted during May and June, while older horses (three- and four-year-olds) did not seroconvert and remained free of respiratory disease, successfully racing throughout the study period [3]. These findings underscore the utility of CF for identifying outbreaks and linking infection to performance outcomes.

Other serological platforms, such as enzyme-linked immunosorbent assays (ELISA), have been developed for ERAV but are less commonly employed in diagnostic settings compared to VNT or CF. The World Organisation for Animal Health (WOAH) recognizes serology as a valuable tool for epidemiological surveillance, particularly in populations where molecular diagnostic infrastructure is limited.

Virus Isolation and Traditional Virology

Virus isolation in cell culture, historically the gold standard for ERAV diagnosis, involves inoculating susceptible cell lines (such as RK-13 cells or primary equine tracheobronchial epithelial cells, TBECs) with clinical specimens and observing for cytopathic effect (CPE). ERAV-infected primary equine tracheobronchial epithelial cells develop characteristic syncytial cell formations and cell clumping, features that are morphologically distinct from some other respiratory viruses [23]. However, ERAV is notoriously fastidious in culture. As noted by Lu et al., the sensitivity of virus isolation varies dramatically between laboratories due to inefficient viral growth in cell culture and the frequent lack of observable CPE, even when viral RNA is present at high copy numbers [11].

This problem is well-illustrated by studies that compared RT-PCR with virus isolation. In one investigation of ERBV (a closely related picornavirus), nested RT-PCR detected viral RNA in six of 17 nasopharyngeal swabs from horses with acute febrile respiratory disease that had previously tested negative by conventional cell culture isolation. Only after multiple blind passages and the addition of 20 mg/mL MgCl₂ to the culture medium was ERBV successfully isolated from one of those six samples [13]. This highlights the practical superiority of molecular methods: RT-PCR can detect ERAV in clinical samples that would be deemed “negative” by traditional virus isolation, thereby providing a more accurate picture of infection prevalence.

Given these challenges, virus isolation is now rarely used as a primary diagnostic tool for ERAV. Its current role is largely confined to research contexts, such as antigenic characterization of field isolates, generation of virus stocks for experimental studies, and investigation of viral pathogenesis. For clinical diagnosis, WOAH and the Centers for Disease Control and Prevention (CDC) guidelines for picornavirus detection strongly advocate for molecular methods, as they offer superior sensitivity, speed, and the ability to detect non-cultivable or poorly replicating strains.

Emerging and Ancillary Diagnostic Technologies

The diagnostic landscape for ERAV is evolving, with several novel approaches offering potential improvements in sensitivity, speed, and non-invasive sampling.

Metagenomic Next-Generation Sequencing

Metagenomic sequencing represents a hypothesis-free, unbiased approach to pathogen discovery and diagnosis. This technique has recently been employed to identify novel and divergent strains of equine rhinitis viruses. For example, metagenomic analysis of a fecal sample from a diarrheic foal in Japan unexpectedly identified a highly divergent ERBV strain with only 62.5–63.1% polyprotein identity to known serotypes, leading to the development of a strain-specific RT-qPCR assay [7]. While this study focused on ERBV, the same approach is directly applicable to ERAV, particularly for detecting genetically distinct variants that may escape detection by conventional PCR assays targeting conserved regions. Metagenomics is also valuable for identifying co-infections with multiple pathogens simultaneously, without the need for pathogen-specific primers [7].

Volatile Organic Compound Profiling

An innovative, non-invasive diagnostic approach under investigation involves the analysis of volatile organic compounds (VOCs) produced as byproducts of cellular metabolism during viral infection. A recent study using headspace solid-phase microextraction and gas chromatography–mass spectrometry (GC-MS) demonstrated that infection of RK-13 cells with different equine viruses, including ERBV, induced distinct VOC signatures that could be separated using principal component analysis [32]. While this technology is still in the preclinical research phase, it holds promise for the development of rapid, point-of-care diagnostic tools that could detect ERAV infection through breath or nasal swab analysis, bypassing the need for complex laboratory infrastructure.

Environmental Surveillance

In settings where direct sampling of individual horses is logistically challenging, environmental surveillance using pooled stall swabs has emerged as a complementary diagnostic strategy. A study conducted during a multi-week equestrian show found that 35% of pooled stall sponges tested PCR-positive for at least one respiratory pathogen, with ERBV detected at a low but quantifiable frequency [21]. Although this approach is less sensitive than direct nasal swab testing from individual horses and cannot identify the specific shedding animal, it provides valuable information about pathogen circulation within a facility, particularly during winter months when respiratory disease incidence is highest [21]. This strategy aligns with the WOAH recommendations for sentinel surveillance in high-risk populations.

Diagnostic Interpretation and Integration with Clinical Data

Ultimately, the interpretation of any diagnostic test for ERAV must be contextualized within the broader clinical picture. A positive qPCR result from a nasal swab does not necessarily equate to active disease causation, as asymptomatic shedding of respiratory viruses, including ERBV, has been documented in healthy sport horses at frequencies of 1.2% [26] and in clinically normal horses participating in shows [22]. To differentiate between infection and disease, clinicians must evaluate viral load, the presence of clinical signs, and the detection or exclusion of other potential pathogens. For ERAV, the highest diagnostic confidence is achieved when a positive qPCR result from a lower respiratory tract sample (e.g., tracheal wash or bronchoalveolar lavage fluid) is accompanied by a compatible clinical syndrome, mucopurulent nasal discharge, cough, fever, and ocular discharge [1], and seroconversion is documented through paired serology.

In summary, the diagnostic approach to ERAV has matured into a multi-faceted discipline. Contemporary best practice mandates the use of validated, multiplex qPCR panels on acutely collected nasal or tracheal wash samples as the first-line diagnostic tool. Serology, particularly VNT and CF tests, retains a crucial role for epidemiological investigations and confirmation of recent infection through paired sampling. Traditional virus isolation is now relegated to specialized research applications, while emerging technologies like metagenomics and VOC profiling may soon expand the diagnostic toolkit further. The informed integration of these diverse diagnostic modalities with meticulous clinical observation remains the cornerstone of effective ERAV management.

Prevention and Control Strategies

The effective management of Equine Rhinitis A Virus (ERAV) within equine populations necessitates a multifaceted, evidence-based approach that integrates targeted biosecurity, strategic vaccination protocols, rigorous diagnostic surveillance, and environmental controls. The pathobiology of ERAV, its close phylogenetic relationship to foot-and-mouth disease virus (FMDV) as an aphthovirus [2], its structural lability at acidic pH [2, 6], and its predilection for young, immunologically naïve horses [1, 3], informs the specific interventions that must be prioritized. The economic and welfare consequences of ERAV infection are substantial, particularly in training and racing operations where the virus has been directly linked to training interruption, failure to race, and prolonged clinical disease in late-born foals [3, 5]. As such, prevention and control must be viewed not as a singular action but as a continuous, adaptive process grounded in epidemiological risk assessment.

Targeted Biosecurity for High-Risk Populations

The epidemiological evidence overwhelmingly identifies young horses, particularly yearlings and two-year-olds entering training facilities, as the demographic most vulnerable to ERAV infection and clinical disease. Rossi et al. [1] documented a yearling-specific incidence risk of 87.9% in a Standardbred training facility, a figure that underscores the explosive transmission potential within this age cohort. This vulnerability is compounded by a significant negative association between increasing age and respiratory disease, with older horses demonstrating serological immunity that protects against clinical signs [1, 3]. The biological basis for this age-related susceptibility is multifactorial, encompassing waning maternal antibody, immunological immaturity, and the physiological stress of training and social mixing. Consequently, any prevention program must prioritize the management of this high-risk demographic upon arrival at congregate facilities.

Isolation protocols for incoming horses, particularly those originating from auction or sale environments, represent a cornerstone of ERAV prevention. Source [1] explicitly recommends that “disease control strategies, such as vaccination programs and isolation of new horses arriving from auction, should be targeted at young animals entering training facilities.” The rationale for isolating auction-origin horses is compelling: these animals are often commingled from diverse geographical origins, experience significant transport stress (a known immunosuppressive factor [14]), and may be shedding virus subclinically. The incubation period for ERAV, combined with the potential for subclinical shedding in the upper respiratory tract, necessitates a minimum quarantine period of 14 to 21 days, during which daily clinical monitoring for pyrexia, mucopurulent nasal discharge, and cough should be conducted [1, 10]. Ideally, incoming horses should be housed in a physically separate barn with dedicated equipment, personnel, and airspace to prevent aerosol or fomite transmission. Contact network analysis has demonstrated that direct and indirect contact patterns among horses within multi-barn facilities are significant determinants of disease spread, and that disruption of these networks through cohort segregation can reduce transmission risk [1, 5].

The timing of introduction into the training population also matters. Rossi et al. [5] demonstrated that late-born foals (February–May birth months) were significantly less likely to recover quickly from ERAV respiratory disease, with a hazard ratio of 0.7 for time to recovery. This finding suggests that younger or less developmentally mature horses entering training later in the season may have prolonged clinical courses, potentially serving as longer-term shedders and amplifying transmission within the cohort. Managers of training facilities should therefore consider age-based cohorting, ensuring that yearlings are not commingled with older, potentially immune horses during the initial weeks of training, and that birth-month stratification is considered when forming training groups.

Facility Design, Ventilation, and Environmental Hygiene

The physical environment of equine housing plays a critical role in the transmission dynamics of ERAV. The virus is shed in high concentrations in nasal secretions and respiratory aerosols [11, 14], and transmission occurs through direct horse-to-horse contact, inhalation of infectious droplets, and contact with contaminated fomites, including feed buckets, water troughs, grooming equipment, and human hands. While ERAV is an enveloped virus structurally related to FMDV, it is notably acid-labile [2]; however, this does not obviate the need for rigorous environmental decontamination, as the virus can survive for sufficient periods on contaminated surfaces to facilitate indirect transmission within barn environments.

Ventilation is paramount. Stables with poor airflow, high humidity, and high stocking density create conditions that favor the accumulation of infectious aerosols. Aerosol transmission of respiratory viruses is well-documented in equine populations, and the structural biology of ERAV suggests that the capsid can undergo massive expansion and genome release under conditions encountered in the respiratory tract [6], indicating that the virus is adapted for efficient transmission via the respiratory route. Barn design should prioritize natural or mechanical ventilation that achieves at least 6–8 air changes per hour, with air intake located away from exhaust outlets to prevent recirculation of contaminated air. During winter months, when stables are often closed to conserve heat, the risk of respiratory pathogen buildup increases substantially. Environmental sampling studies have demonstrated that respiratory pathogens, including ERBV and equine herpesviruses, are detected with greater frequency in stall samples during colder months [21]. Although this study did not specifically assess ERAV, the principle of seasonal risk elevation applies broadly to respiratory viruses in horses.

Environmental disinfection protocols must be tailored to the physicochemical properties of ERAV. As an aphthovirus, ERAV is highly sensitive to low pH environments; exposure to acidic disinfectants (pH below 6.0) is likely to induce capsid dissociation into pentameric subunits, rendering the virus non-infectious [2]. This is a critical insight because it differentiates ERAV from many other equine respiratory viruses that require different inactivation strategies. Quaternary ammonium compounds, diluted bleach solutions (sodium hypochlorite at 0.1–0.5%), and accelerated hydrogen peroxide formulations are effective against picornaviruses, but care must be taken to ensure adequate contact time and removal of organic matter, which can neutralize disinfectant activity. High-touch surfaces, including stall fronts, waterers, feed tubs, door handles, and trailer ramps, should be cleaned and disinfected daily during outbreak situations. Personnel should be instructed to wash hands or use alcohol-based sanitizers between handling different horses, particularly when moving from known infected or high-risk (young) horses to older or convalescent animals.

Vaccination Strategy and Immunological Considerations

Currently, there is no widely available commercial ERAV-specific vaccine licensed for use in horses. This represents a critical gap in prevention capabilities. The development of an effective ERAV vaccine is complicated by several factors inherent in the virus’s biology. ERAV belongs to the genus Aphthovirus, and its capsid structure demonstrates significant plasticity, with the VP1 protein diverging substantially from that of FMDV and exhibiting a pitted surface architecture [2]. The structural protein VP1 is a primary target for neutralizing antibodies, and its variability may pose challenges for cross-protection across different ERAV strains. However, the close phylogenetic relationship between ERAV and FMDV [2] provides a useful framework for vaccine design, as FMDV vaccines, particularly inactivated whole-virus formulations and virus-like particle (VLP) vaccines, have been successfully deployed for decades in livestock as part of global control and eradication programs endorsed by the World Organisation for Animal Health (WOAH). The principles underlying FMDV vaccination, including the importance of inducing high-titer neutralizing antibodies directed against the intact capsid to prevent cellular entry and uncoating, are directly translatable to ERAV.

Vaccination strategies for ERAV would ideally target the high-risk yearling and two-year-old population prior to entry into training facilities. A primary series of two doses administered 3–4 weeks apart, followed by a booster at 6 months, would be necessary to establish solid immunity in naïve horses. The structural biology of ERAV cell entry reveals that the virus uncoats via a two-step process involving the transient formation of an 80S empty particle following genome release, which then dissociates into pentamers at acidic pH [2]. Neutralizing antibodies that bind to the native virion and prevent this uncoating process, either by stabilizing the capsid against expansion or by blocking receptor attachment, would be the primary correlate of protection. The expanded ERAV particle structure reported by Bakker et al. [6] demonstrates that genome exit likely occurs through large pores that form at the three-fold axes of the capsid, a mechanism that could potentially be blocked by antibodies directed against VP2 or VP3, which form the core structural framework of the particle.

Given the absence of a licensed ERAV vaccine, practitioners must rely on comprehensive vaccination against other respiratory pathogens, specifically equine influenza virus (EIV), equine herpesvirus types 1 and 4 (EHV-1, EHV-4), and Streptococcus equi subspecies equi, to reduce the overall burden of respiratory disease and minimize the risk of secondary bacterial infections that can complicate ERAV infection. Viral damage to the respiratory epithelium, particularly loss of ciliated cells and goblet cells, creates a permissive environment for secondary bacterial colonization, as has been demonstrated for equine influenza [27]. While that study focused on influenza, the principle of viral-bacterial synergy applies broadly to respiratory viruses, including ERAV. Protecting the airway mucosa through vaccination against common viral pathogens reduces the cumulative insult and the window of opportunity for opportunistic bacteria.

Research into ITAF45 as a host factor essential for ERAV translation [15] raises the intriguing possibility of antiviral drug development. ITAF45, a cellular protein that binds to the type II internal ribosome entry site (IRES) of ERAV RNA, is required for efficient translation initiation. CRISPR/Cas9 knockout of ITAF45 conferred resistance to ERAV infection in cell lines [15], identifying this protein as a promising target for host-directed antivirals. Such agents, if developed, could serve as prophylactic or therapeutic tools in outbreak settings, particularly in high-risk young horses. However, translation of this finding into an approved veterinary pharmaceutical will require substantial investment in drug discovery, safety testing, and regulatory approval.

Diagnostic Surveillance and Early Detection

The foundation of any effective control program is the ability to rapidly and accurately detect ERAV infection. The development of real-time reverse transcription PCR (rRT-PCR) assays targeting the 5′ untranslated region (5′ UTR) of the ERAV genome has provided a sensitive, specific, and rapid diagnostic tool that can detect as few as one plaque-forming unit per milliliter [11]. These assays can distinguish ERAV from ERBV and do not cross-react with other common equine respiratory pathogens, including EHV-1, EHV-4, EIV, or S. equi [11]. The adoption of molecular diagnostics has revolutionized the identification of ERAV in clinical settings, circumventing the limitations of virus isolation, which is often hampered by inefficient viral growth in cell culture and lack of cytopathic effect [11, 13].

For control purposes, diagnostic testing should be employed at several strategic junctures. First, any horse presenting with acute onset of fever, mucopurulent nasal discharge, cough, or ocular discharge, particularly if the horse is young and has recently entered a training facility, should be tested for ERAV using rRT-PCR on nasopharyngeal swabs [3, 10, 20]. The timing of sample collection is critical; acutely collected samples from the first 24–72 hours of clinical illness are most likely to yield positive results, as viral shedding is highest during this window [30]. Second, facilities experiencing an outbreak should implement cohort testing of all in-contact horses, including those without clinical signs, as subclinical shedders are well-documented for ERAV and can perpetuate transmission [22, 26, 35]. Third, surveillance testing of healthy horses prior to movement, such as before entry to a show, sale, or training facility, can identify asymptomatic carriers and prevent introduction into naïve populations.

The voluntary biosurveillance programs established in the United States, which have tested over 10,000 equids for ERAV and other respiratory pathogens, provide a model for ongoing monitoring [20, 34]. These programs have demonstrated that ERAV is detected at lower frequencies than EIV or EHV-4 in horses with acute respiratory signs (approximately 2.3% overall [20]), but that this figure likely underestimates true prevalence due to the self-selecting nature of submissions and the lack of routine testing for ERAV in many diagnostic panels. Inclusion of ERAV in standardized respiratory PCR panels is essential for comprehensive surveillance and timely outbreak detection.

During outbreaks, control measures must be escalated. Affected horses should be isolated immediately, ideally in a separate barn with dedicated airflow and personnel. Movement of horses into or out of the affected facility should be halted until all cases have resolved and a minimum of 14 days have passed since the last clinical case. Disinfection protocols should be intensified, and personnel should adhere to strict hygiene procedures, including the use of dedicated boots, coveralls, and gloves when handling infected horses [1, 21]. Environmental monitoring, such as PCR testing of stall surfaces, can be used to confirm the effectiveness of disinfection and to identify persistent environmental contamination [21, 26]. Although environmental testing should not replace direct surveillance of horses, it provides a complementary tool for monitoring pathogen burden in the barn environment.

The Role of Nutrition, Stress Management, and Antioxidant Status

Emerging evidence suggests that host factors, including nutritional status and oxidative stress, may influence susceptibility to and recovery from ERAV infection. Bażanów et al. [4] demonstrated that horses with ERAV antibody titers greater than 1:64 had statistically higher plasma concentrations of total superoxide dismutase (SOD) and copper-zinc SOD (CuZnSOD) compared to horses with lower titers. This finding suggests that the antiviral immune response generates significant oxidative stress, and that horses in the convalescent phase may have an upregulated antioxidant defense system to mitigate this damage. While this study could not establish causation, it raises the hypothesis that nutritional support with antioxidants, including vitamin E, selenium, and glutathione precursors, may facilitate recovery and reduce the duration of clinical disease in infected horses.

Stress is a well-documented precipitant of respiratory viral infections in horses [14]. Transportation, weaning, changes in social grouping, initiation of training, and concurrent illness all elevate circulating cortisol levels, which can suppress cell-mediated immunity and increase susceptibility to viral infection. In the context of ERAV control, management practices that minimize physiological stress are therefore an integral component of prevention. This includes gradual acclimatization to new facilities, maintenance of stable social groups, provision of adequate turnout and exercise, and careful attention to nutritional needs during periods of high training demand. Young horses entering training should be given a period of adjustment before exposure to the full training regimen, and their respiratory health should be monitored closely during the first 4–8 weeks.

Coordinated Outbreak Response and Regulatory Considerations

Effective control of ERAV requires a coordinated response that involves stable managers, veterinarians, diagnostic laboratories, and in some jurisdictions, animal health authorities. While ERAV is not a reportable disease in most countries, unlike FMDV, which is subject to strict international trade restrictions under WOAH guidelines, the economic impact on the performance horse industry warrants a serious approach. In the United Kingdom and Ireland, research has highlighted the link between ERAV seroconversion and failure to race, underscoring the financial stakes for owners and trainers [3]. Facilities experiencing recurrent outbreaks should engage with veterinary epidemiologists to identify underlying risk factors, such as high stocking density, inadequate ventilation, or poor biosecurity compliance, and implement corrective actions.

Quarantine protocols modeled on those used for EHV-1 myeloencephalopathy control have proven effective in preventing spread of respiratory viruses in show and training environments [22]. Following EHV-1 outbreaks in California, mandatory qPCR testing of clinically healthy horses and a period of quarantine successfully eliminated further cases and facilitated safe return to competition [22]. Similar principles apply to ERAV: during an outbreak, testing of all horses in the affected cohort, isolation of positive animals, and restriction of movement for a defined incubation period (typically 14–21 days) are evidence-based interventions that can contain the virus.

In conclusion, the prevention and control of ERAV demands a comprehensive, risk-based approach that exploits the virus’s biological vulnerabilities, particularly its acid lability and age-specific pathogenesis, while compensating for the current absence of a licensed vaccine. Targeted biosecurity for young horses entering training, rigorous environmental hygiene, molecular surveillance, stress reduction, and proactive outbreak management are the pillars of an effective control program. As research into ERAV’s host interactions and structural biology progresses, the development of specific vaccines and potential antiviral agents will further strengthen the equine clinician’s armamentarium against this underappreciated but economically significant pathogen.

Immune Response and Vaccination

The host immune response to Equine Rhinitis A Virus (ERAV) is a complex, multifaceted process that begins at the mucosal surface of the equine respiratory tract and involves both innate and adaptive arms of the immune system. Understanding this response is critical not only for elucidating the pathogenesis of ERAV-induced respiratory disease but also for the rational design of effective vaccination strategies. Despite the virus’s significant impact on young racehorses, as evidenced by seroconversion rates of 75% among clinical cases and yearling attack rates reaching 87.9% [1, 5], the development and deployment of targeted vaccines remain surprisingly limited. This section provides an exhaustive analysis of the innate immune mechanisms, the humoral and cell-mediated adaptive responses, the correlates of protection, and the current state and future directions of vaccination against ERAV.

Innate Immune Responses and Mucosal Barriers

The initial encounter between ERAV and the equine host occurs at the respiratory epithelium. The virus, an aphthovirus within the Picornaviridae family, must overcome physical barriers such as mucus and the mucociliary escalator before gaining entry to susceptible cells. Upon successful infection of primary tracheobronchial epithelial cells (TBECs), a cascade of innate immune events is triggered. In vitro studies using equine TBECs have demonstrated that ERAV infection induces the formation of syncytial cell formations and cell clumping, a cytopathic effect distinct from that seen with other respiratory viruses [23]. This direct cytopathology compromises the integrity of the epithelial barrier, potentially facilitating secondary bacterial infections, a phenomenon well-documented in other equine respiratory viral infections such as equine influenza [27].

At the molecular level, the innate response is characterized by the rapid upregulation of pro-inflammatory cytokines and chemokines. Crucially, research has shown that ERAV infection of TBECs leads to a significant upregulation of interleukin-8 (IL-8) within hours of exposure, a response that persists for at least 24 hours [23]. IL-8 is a potent chemoattractant for neutrophils and plays a pivotal role in the recruitment of inflammatory cells to the site of infection. This chemokine response is likely a key driver of the mucopurulent nasal discharge observed in over 62% of naturally infected horses [1]. Interestingly, the same study reported that significant changes in the expression of interferons (IFN-β, IFN-γ) and IL-4 were not detectable within the first 24 hours post-infection in this in vitro model [23]. This suggests that ERAV may possess mechanisms to subvert or delay the type I interferon response, a common strategy among picornaviruses, allowing it to establish infection before a robust antiviral state is achieved. The lack of a strong early interferon signature may also explain the relatively prolonged clinical course observed in some horses, with a median time to recovery of 6 days but a range extending to 32 days [5].

Further insights into the host-virus interaction at the cellular level come from studies on viral translation. ERAV, like all picornaviruses, relies on an internal ribosome entry site (IRES) within its 5’ untranslated region to hijack the host’s translational machinery. A critical host factor for this process is ITAF45 (also known as PA2G4/EBP1). Recent research has demonstrated that ITAF45 is an essential IRES trans-acting factor (ITAF) for ERAV and other type II IRES-containing picornaviruses, including foot-and-mouth disease virus (FMDV) [15]. Knockout of ITAF45 in cell lines confers resistance to ERAV infection, highlighting this protein as a potential target for novel antiviral therapies [15]. This dependency on a specific host factor underscores the intricate co-evolutionary relationship between the virus and the equine host’s translational apparatus.

Humoral Immune Response and Serological Correlates of Protection

The adaptive humoral response, particularly the production of neutralizing antibodies, is considered the primary correlate of protection against ERAV. Natural infection elicits a robust and durable antibody response. Serological surveys have consistently demonstrated a high prevalence of ERAV-specific antibodies in horse populations worldwide. For instance, a study in Poland using virus neutralization tests (VNT) found that 72% of serum samples from clinically healthy horses were seropositive [4]. Similarly, seroepidemiological studies in Mongolia have confirmed the widespread prevalence of ERAV antibodies, indicating that exposure is common across diverse geographic regions and management systems [18].

The kinetics of the antibody response are closely linked to clinical disease. In a longitudinal study of Thoroughbred racehorses, seroconversion to ERAV, detected by complement fixation (CF), frequently correlated with clinical respiratory disease and was significantly associated with subsequent failure to race (p = 0.0009) [3]. This finding underscores the direct economic impact of ERAV infection on the racing industry. The study also revealed a striking age-dependent pattern of seroconversion: over 55% of two-year-olds seroconverted during a two-month period in the spring, while only one seroconversion was observed among older horses (three- and four-year-olds) [3]. This age-related susceptibility is a hallmark of ERAV epidemiology and is corroborated by other studies showing that yearling horses are at significantly increased risk of clinical disease compared to older cohorts [1, 5]. The negative association between increasing age and respiratory disease (OR = 0.011) suggests that prior exposure and the development of protective immunity are the primary drivers of this pattern [1].

The presence of maternally derived antibodies (MDA) in foals is a critical factor influencing the timing of natural infection and the efficacy of vaccination. While specific data on MDA duration for ERAV is limited, it is well-established for other equine respiratory viruses. The waning of MDA in foals, typically between 4 and 9 months of age, creates a window of susceptibility that coincides with the high-risk period for yearlings entering training facilities [1, 5]. This immunological gap is a major challenge for vaccination programs.

Cell-Mediated Immunity and Viral Clearance

While humoral immunity is crucial for preventing reinfection, cell-mediated immunity (CMI) is essential for clearing established viral infections. The role of T-cell responses in ERAV infection is less well-characterized than the antibody response, but it is undoubtedly important. The association between ERAV detection and airway inflammation provides indirect evidence of a robust cellular response. In studies of racehorses, the detection of ERAV (and ERBV) in tracheal washes was significantly associated with an increased proportion of neutrophils in bronchoalveolar lavage fluid (BALF) [28]. Furthermore, ERBV detection in tracheal washes has been identified as a major risk factor for coughing (OR 5.3; 95% CI 2.1-14.0) [24]. This neutrophilic inflammation is a hallmark of the adaptive immune response, driven by the recruitment of T cells and the subsequent release of cytokines that orchestrate the inflammatory cascade.

The process of viral clearance is intimately linked to the destruction of infected cells. The massive structural expansion of the ERAV capsid, which involves the loss of the internal VP4 protein and the RNA genome, is a prerequisite for genome release and cell entry [2, 6]. This uncoating process exposes viral peptides on the surface of infected cells via major histocompatibility complex (MHC) class I molecules, making them targets for cytotoxic T lymphocytes (CTLs). The subsequent lysis of infected cells, while effective at eliminating the viral reservoir, contributes to the clinical signs of respiratory disease, including epithelial damage and inflammation.

Vaccination Strategies: Current Status and Future Directions

Despite the clear economic and welfare impact of ERAV, there is currently no widely available, commercially licensed vaccine specifically for this virus in most parts of the world. This represents a significant gap in equine respiratory disease control. The development of an effective ERAV vaccine faces several challenges, including the need to induce robust mucosal immunity, the presence of multiple serotypes (particularly for ERBV), and the high cost of vaccine development for a pathogen that is often underdiagnosed.

The most promising vaccine platforms for ERAV would likely be based on inactivated whole-virus or modified-live virus (MLV) technologies, similar to those used successfully for other equine respiratory viruses like equine influenza and equine arteritis virus (EAV) [29]. An inactivated vaccine would offer a high safety profile, while an MLV vaccine might induce a more robust and longer-lasting immune response, including CMI. However, the potential for reversion to virulence is a concern with MLV vaccines. The use of viral vector vaccines, such as those based on canarypox or adenovirus, expressing the ERAV capsid proteins (VP1, VP2, VP3, VP0) could also be a viable strategy, as they can induce both humoral and cellular immunity without the risk of causing disease.

The 2A peptide from ERAV (E2A) has been extensively studied and is widely used in molecular biology for polycistronic gene expression [16, 17, 19]. This peptide mediates a “cleavage” event during translation, allowing for the co-expression of multiple proteins from a single open reading frame. This technology could be leveraged in the design of a recombinant vaccine, where the ERAV structural proteins are co-expressed with immunostimulatory molecules to enhance the immune response. The fact that E2A has been shown to be non-immunogenic in immunocompetent individuals is a significant advantage for its use in vaccine vectors [16].

A critical consideration for any ERAV vaccination program is the timing of administration. Given the high incidence of disease in yearlings entering training facilities [1, 5], a vaccination schedule should aim to prime the immune system before this high-risk period. This would likely involve a primary series of two or three doses starting at 4-6 months of age, followed by a booster prior to weaning or entry into training. The interference from MDA must be carefully considered, as high levels of maternal antibodies can neutralize vaccine antigens and prevent the development of an active immune response. A prime-boost strategy, using a different vaccine platform for the booster dose, could help overcome MDA interference.

Furthermore, the development of a bivalent or multivalent vaccine that includes both ERAV and ERBV would be highly advantageous, given that both viruses circulate in the same populations and cause similar clinical signs [8, 10, 14, 20]. The increasing frequency of ERBV detection in diagnostic samples, often as a co-infection with other pathogens like Streptococcus equi subsp. equi and equine herpesvirus-4 [8, 10, 30], underscores the need for comprehensive respiratory vaccines. The World Organisation for Animal Health (WOAH) recognizes the importance of controlling equine respiratory diseases, and the development of effective vaccines is a key component of this strategy. The implementation of voluntary biosurveillance programs, such as those in the United States, is critical for monitoring the circulation of ERAV and ERBV and for evaluating the potential impact of future vaccination campaigns [20, 34]. Without a concerted effort to develop and deploy effective vaccines, ERAV will continue to be a significant cause of morbidity, training interruption, and economic loss in the equine industry, particularly among the young, athletic horses that are most vulnerable to its effects.

References

[1] Rossi T, Moore A, O’Sullivan T, Greer A. Equine Rhinitis A Virus Infection at a Standardbred Training Facility: Incidence, Clinical Signs, and Risk Factors for Clinical Disease. Frontiers in Veterinary Science. 2019. DOI: https://doi.org/10.3389/fvets.2019.00071

[2] Tuthill T, Harlos K, Walter T, Knowles N, Groppelli E, Rowlands D, et al.. Equine Rhinitis A Virus and Its Low pH Empty Particle: Clues Towards an Aphthovirus Entry Mechanism?. PLoS Pathogens. 2009. DOI: https://doi.org/10.1371/journal.ppat.1000620

[3] Back H, Weld J, Walsh C, Cullinane A. Equine Rhinitis A Virus Infection in Thoroughbred Racehorses, A Putative Role in Poor Performance?. Viruses. 2019. DOI: https://doi.org/10.3390/v11100963

[4] Bażanów B, Frącka A, Jackulak N, Romuk E, Gębarowski T, Owczarek A, et al.. Viral, Serological, and Antioxidant Investigations of Equine Rhinitis A Virus in Serum and Nasal Swabs of Commercially Used Horses in Poland. BioMed Research International. 2018. DOI: https://doi.org/10.1155/2018/8719281

[5] Rossi T, Moore A, O’Sullivan T, Greer A. Risk factors for duration of Equine Rhinitis A Virus respiratory disease.. Equine Veterinary Journal. 2019. DOI: https://doi.org/10.1111/evj.13204

[6] Bakker SE, Groppelli E, Pearson A, Stockley P, Rowlands D, Ranson N. Limits of Structural Plasticity in a Picornavirus Capsid Revealed by a Massively Expanded Equine Rhinitis A Virus Particle. Journal of Virology. 2014. DOI: https://doi.org/10.1128/JVI.01979-13

[7] Ketphan W, Sato M, Tsujimura K, Mizutani T, Takemae H. Identification of a novel equine rhinitis B virus detected in horse from Japan. Journal of Veterinary Medical Science. 2025. DOI: https://doi.org/10.1292/jvms.25-0379

[8] Schneider C, James K, Craig B, Chappell D, Vaala W, Harreveld PDv, et al.. Characterization of Equine Rhinitis B Virus Infection in Clinically Ill Horses in the United States during the Period 2012–2023. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12111324

[9] Stasiak K, Dunowska M, Rola J. Prevalence and Sequence Analysis of Equine Rhinitis Viruses among Horses in Poland. Viruses. 2024. DOI: https://doi.org/10.3390/v16081204

[10] Bernardino P, James K, Barnum S, Corbin R, Wademan C, Pusterla N. What have we learned from 7 years of equine rhinitis B virus qPCR testing in nasal secretions from horses with respiratory signs.. The Veterinary Record. 2021. DOI: https://doi.org/10.1002/vetr.26

[11] Lu Z, Timoney P, White J, Balasuriya UBR. Development of one-step TaqMan® real-time reverse transcription-PCR and conventional reverse transcription-PCR assays for the detection of equine rhinitis A and B viruses. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-120

[12] Woo P, Lau S, Choi GK, Huang Y, Wernery R, Joseph S, et al.. Equine rhinitis B viruses in horse fecal samples from the Middle East. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0547-x

[13] Black W, Hartley C, Ficorilli N, Studdert M. Reverse transcriptase-polymerase chain reaction for the detection equine rhinitis B viruses and cell culture isolation of the virus. Archives of Virology. 2006. DOI: https://doi.org/10.1007/s00705-006-0810-3

[14] Frippiat T, Wollenberg Lvd, Erck-Westergren Ev, Maanen Kv, Votion D. Respiratory viruses affecting health and performance in equine athletes.. Virology. 2024. DOI: https://doi.org/10.1016/j.virol.2024.110372

[15] Bellucci MA, Amiri M, Berryman S, Moshari A, Owino CO, Luteijn R, et al.. ITAF45 is a pervasive trans-acting factor for picornavirus Type II IRES elements. bioRxiv. 2025. DOI: https://doi.org/10.1073/pnas.2506281122

[16] Arber C, Abhyankar H, Heslop HE, Heslop HE, Brenner MK, Brenner MK, et al.. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Therapy. 2013. DOI: https://doi.org/10.1038/gt.2013.25

[17] Zhu X, Ricci-Tam C, Hager ER, Sgro A. Self-cleaving peptides for expression of multiple genes in Dictyostelium discoideum. PLoS ONE. 2023. DOI: https://doi.org/10.1371/journal.pone.0281211

[18] Pagamjav O, Kobayashi K, Murakami H, Tabata Y, Miura Y, Boldbaatar B, et al.. Serological survey of equine viral diseases in Mongolia. Microbiology and immunology. 2011. DOI: https://doi.org/10.1111/j.1348-0421.2011.00312.x

[19] Chng J, Wang T, Nian R, Lau A, Hoi KM, Ho SCL, et al.. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. mAbs. 2015. DOI: https://doi.org/10.1080/19420862.2015.1008351

[20] Pusterla N, James K, Barnum S, Bain F, Barnett D, Chappell D, et al.. Frequency of Detection and Prevalence Factors Associated with Common Respiratory Pathogens in Equids with Acute Onset of Fever and/or Respiratory Signs (2008–2021). Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11070759

[21] Lawton K, Runk D, Hankin S, Mendonsa E, Hull D, Barnum S, et al.. Detection of Selected Equine Respiratory Pathogens in Stall Samples Collected at a Multi-Week Equestrian Show during the Winter Months. Viruses. 2023. DOI: https://doi.org/10.3390/v15102078

[22] Wilcox A, Barnum S, Wademan C, Corbin R, Escobar E, Hodzic E, et al.. Frequency of Detection of Respiratory Pathogens in Clinically Healthy Show Horses Following a Multi-County Outbreak of Equine Herpesvirus-1 Myeloencephalopathy in California. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11101161

[23] Pusterla N, Kass P, Mapes S, Johnson CK, Barnett D, Vaala W, et al.. Voluntary surveillance program for important equine infectious respiratory pathogens in the United States.. . 2016. DOI: https://doi.org/10.1016/J.JEVS.2016.02.169

[24] Doubli-Bounoua N, Richard E, Léon A, Pronost S, Fortier G. Association between virus detection/quantification and clinical signs of airway inflammation in horses at training. Journal of Equine Veterinary Science. 2016. DOI: https://doi.org/10.1016/J.JEVS.2016.02.172

[25] Ren Y, Lin Q, Berro J. 2A peptide from ERBV-1 efficiently separates endogenous protein domains in the fission yeast Schizosaccharomyces pombe. microPublication Biology. 2023. DOI: https://doi.org/10.17912/micropub.biology.000941

[26] Pusterla N, Sandler-Burtness E, Barnum S, Hill LA, Mendonsa E, Khan RQ, et al.. Frequency of detection of respiratory pathogens in nasal secretions from healthy sport horses attending a spring show in California.. Journal of Equine Veterinary Science. 2022. DOI: https://doi.org/10.1016/j.jevs.2022.104089

[27] Muranaka M, Yamanaka T, Katayama Y, Niwa H, Oku K, Matsumura T, et al.. Time-related Pathological Changes in Horses Experimentally Inoculated with Equine Influenza A Virus. Journal of Equine Science. 2012. DOI: https://doi.org/10.1294/jes.23.17

[28] Couetil L, Ivester K, Barnum S, Pusterla N. Equine respiratory viruses, airway inflammation and performance in thoroughbred racehorses.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109070

[29] Glaser A, Chirnside ED, Horzinek MC, Vries ADd. Equine arteritis virus. Theriogenology. 1997. DOI: https://doi.org/10.1016/S0093-691X(97)00107-6

[30] Snedden K, Frye E, Conklin R, Aprea M, Rishniw M, Lejeune M, et al.. A retrospective analysis of canine, feline, and equine respiratory polymerase chain reaction panels performed at the New York State Animal Health Diagnostic Center (January-December 2023).. Journal of the American Veterinary Medical Association. 2025. DOI: https://doi.org/10.2460/javma.24.11.0755

[31] Pusterla N, James K, Mapes S, Bain F. Frequency of molecular detection of equine coronavirus in faeces and nasal secretions in 277 horses with acute onset of fever. The Veterinary Record. 2019. DOI: https://doi.org/10.1136/vr.104919

[32] Matczuk A, Wolska J, Olszowy M, Kublicka A, Szumowski A, Kokocińska-Alexandre A, et al.. Volatile Organic Compounds Induced upon Viral Infection in Cell Culture: Uniform Background Study with Use of Viruses from Different Families. Molecules. 2025. DOI: https://doi.org/10.3390/molecules30234642

[33] Dumrath CA, Medina‐Torres CE, Bartmann C, Wagner B, Goehring L. Innate and specific immune responses to intranasal modified-live EHV-1 virus vaccination in previously immunised equids - a pilot. Journal of Equine Veterinary Science. 2016. DOI: https://doi.org/10.1016/J.JEVS.2016.02.173

[34] Chappell D, Barnett D, James K, Craig B, Bain F, Gaughan E, et al.. Voluntary Surveillance Program for Equine Influenza Virus in the United States during 2008–2021. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12020192

[35] Biava JS, Finger MA, Ullmann L, Biondo A, Leutenegger C, Filho IRB. PSVII-37 First molecular detection of Equine Herpesvirus type 2 (EHV-2) and type 5 (EHV-5) in upper respiratory liquids of healthy training horses from southern Brazil. Journal of Animal Science. 2019. DOI: https://doi.org/10.1093/jas/skz258.636